North America Disposable Endoscopes Market Size | Companies
The North America disposable endoscopes market size was exhibited at USD 1.56 billion in 2024 and is projected to hit around USD 3.31 billion by 2034, growing at a CAGR of 7.80% during the forecast period 2024 to 2034.
| Report Coverage | Details |
| Market Size in 2025 | USD 1.68 Billion |
| Market Size by 2034 | USD 3.31 Billion |
| Growth Rate From 2024 to 2034 | CAGR of 7.80% |
| Base Year | 2024 |
| Forecast Period | 2024-2033 |
| Segments Covered | Type, End-use, Country |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional scope | North America |
| Key Companies Profiled | Olympus Corporation; Boston Scientific Corporation; PENTAX Medical (Hoya Corporation); FUJIFILM Holdings Corporation; Karl Storz GmbH & Co., KG; Stryker; Medtronic; Ambu A/S; STERIS plc. |
The rise in the prevalence of gastrointestinal disorders and various cancer cases is boosting the adoption & market growth of disposable endoscopes. For instance, according to the American Cancer Society, colorectal cancer is the second leading cause of cancer-related deaths in the U.S., with an estimated number of 153,020 individuals diagnosed with colorectal cancer in 2023. Furthermore, growing respiratory and chronic disorders fuel the market growth.
The increasing prevalence of cancer and cancer-related mortality in this region is one of the factors anticipated to propel the market. For instance, according to the Cancer Progress Report 2023 published by the American Cancer Society, in 2023, around 1,958,310 new cancer cases were diagnosed in the U.S. Projections indicate that by 2040, the number of new cancer cases is expected to reach 2.3 million. As the prevalence of cancer increases, there is a rising need for effective diagnostic and treatment procedures. Disposable endoscopes play a crucial role in offering minimally invasive options to accurately diagnose, stage, and treat various forms of cancer.
Furthermore, to eliminate the risk of pathogen contamination from the reusable endoscopes, the clinical staff undergo lengthy sterilization steps, which are tedious and become more time-consuming. For instance, according to Boston Scientific Corporation, more than 100 series of manual steps are required to clean endoscopes during ERCP procedures to reuse, which is susceptible to manual errors. In addition, the increasing recommendation by the regulatory authorities, such as the U.S. FDA, for developing disposable endoscopic devices and components to improve cleaning and reduce the risk of patient infection is supporting market growth.
In addition, factors such as favorable reimbursement policies and commercialization of new products are anticipated to fuel market growth. For instance, in July 2022, Zsquare, a manufacturer of single-use endoscopes, received a U.S. FDA 510K clearance for its Zsquare ENT-Flex Rhinolaryngoscop to use in diagnostic ENT procedures. The improved design offers physicians with high-resolution imaging with a cost-effective option for single-use endoscopy, featuring the smallest diameter endoscope shaft.
Furthermore, the demand for disposable endoscopes is growing due to the rising concerns regarding cross-contamination risks associated with reusable endoscopes. This growing focus on patient safety has increased innovation and regulatory actions aimed at enhancing the availability & quality of disposable endoscopes. For instance, in August 2021, Boston Scientific’s EXALT Model B Bronchoscope received 510(k) clearance from the FDA. This single-use bronchoscope is designed for bedside procedures in Intensive Care Units (ICUs) and Operating Rooms (ORs), addressing the need for safer alternatives to reusable devices.
The advantages of using disposable endoscopes, such as the lower chance of cross-contamination, cost-effectiveness, and minimum resource utilization, are anticipated to accelerate market growth. Increasing technological advancements and growing manufacturer investments to innovate and develop new single-use endoscopic devices are significant factors supporting the market's growth during the forecast period.
The gastrointestinal endoscopes segment dominated the market with revenue share of 56.6% in 2024. The U.S. dominated the disposable endoscopes market in North America in 2024. Factors such as the shift towards minimally invasive surgeries, technological advancements, a growing prevalence of gastrointestinal disorders, and healthcare settings and government encouraging individuals to perform routine screenings for cancer increase the demand for diagnostic procedures. For instance, according to the American Cancer Society estimates , approximately 26,890 new cases and 10,880 deaths from stomach cancer in the U.S. in 2024.
The laparoscopes segment is expected to witness fastest CAGR growth during the forecast period. The U.S. FDA recently approved various disposable bronchoscopes, which are anticipated to increase the availability of these devices in the market and drive segment growth. For instance, in 2023, Xenocor, a medical device company, received U.S. FDA clearance for its Saberscope, an articulating, fog-free, single-use laparoscope.
The outpatient facilities’ segment dominated the market in 2024 and accounted for the largest revenue share of 54.0%. Favorable government initiatives and reimbursement policies boost the segment growth. For instance, In the U.S., as per the 2022 GI Endoscopy Coding and Reimbursement Guide, outpatient hospitals receive the highest reimbursement of USD 3,135.9 for diagnostic therapy, according to CPT code 43260. This reimbursement is the National Medicare Average. In addition, the reimbursement for facilities at the ambulatory surgery center is USD 1,400.9. The increase in reimbursement from 2019 to 2022 signifies better reimbursement frameworks for GI endoscopy, along with an increasing number of patients opting for the same
The hospitals segment is anticipated to register a significant growth over the forecast period. Factors such as the rise in patients suffering from various chronic diseases and the consequent increase in surgical procedures fuel the segment growth. Compared to other healthcare settings, hospitals witness a significantly higher inflow of patients for bariatric surgeries or other endoscopic procedures, owing to the ease of handling any emergencies that may arise during surgical procedures and the availability of a wide range of treatment options in such facilities. For instance, according to an article published by Becker’s Hospital Review, over 3,000 hospitals utilize disposable bronchoscopes provided by Ambu A/S.
North America Disposable Endoscopes Market Trends
The market is fueled by rapid technological advancements, leading to the development of new and innovative endoscopic devices in this region. These technological breakthroughs have improved the adoption of endoscopes. For instance, in October 2022, OMNIVISION, a manufacturer of semiconductor solutions, collaborated with AdaptivEndo, a technology disruptor in single-use endoscopes, to develop a flexible and unified platform. This new platform is designed to apply single-use and hybrid endoscopes across various medical specialties, such as urology, gastroenterology, gynecology, and sophisticated endoscopic surgery.
U.S. Disposable Endoscopes Market Trends
The U.S. dominated the disposable endoscopes market in North America in 2024. The high prevalence of several diseases, such as gastrointestinal (GI) disorders, respiratory conditions, urological problems, gynecological issues, and cancer, is increasing the need for endoscopic procedures for diagnosis & treatment in North America. For instance, according to a report by ResearchGate, it is projected that there will be 2,001,140 new cases of cancer and 611,720 cancer-related deaths in the U.S. in 2024. Thus, the growing need for accurate and minimally invasive diagnostic tools drives market growth.
Key participants in the North America disposable endoscopes market are focusing on developing innovative business growth strategies in the form of product portfolio expansions, mergers & acquisitions, partnerships & collaborations, and geographical expansions.
In April 2024, Ambu A/S received U.S. FDA approval for its aScope Gastro Large, a single-use therapeutic gastroscope. It enables healthcare practitioners to manage a broader range of clinical needs across operating rooms (ORs), intensive care units (ICUs), and endoscopy suites.
In April 2023, Verathon, a medical device company , launched the BFlex2, a single-use bronchoscope series. It offers four distinct scope sizes and incorporates novel features to improve clinicians' capabilities in managing the diverse needs of pediatric and adult patients.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the North America disposable endoscopes market
Type
End-use
Country
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers